Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Integrated Global Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

IQVIA TECHNOLOGIES

"Harness technology for a healthier world.

EXPLORE MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.

COMPLIANCE OVERVIEW
Integrated Global Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

Webinar

"Global Consumer Health Trends 2023 Webinar Series

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Getting the diagnostics for CDI just right
Monique J Menezes, Analyst, BBC IVD Solutions & MedTech CoE, IQVIA
Kristen Johnson, Consultants, IVD Solutions
Jan 28, 2019
  • Blogs
  • Getting the diagnostics for CDI just right

The issues in CDI testing

While there are diagnostic tests for CDI, some are regarded as too sensitive and others not sensitive enough. In the hunt for a "just right" solution, healthcare professionals generally have their own preferences when it comes to testing for CDIs. However, without a clear consensus on CDI testing guidelines, conflicting recommendations have escalated these opinions into a full-scale controversy.

There are two major choices of technology when it comes to CDI detection. Historically, the most common is enzyme immunoassay (EIA). While this option is fast and relatively inexpensive, those opposed to using it for CDI diagnosis worry about its lack of sensitivity. This lower sensitivity could mean that patients are left untreated, at risk of serious illness and death, and could spread infection to others.

The other option, nucleic acid amplification testing (NAAT), detects the presence of C. difficile colonization and is known for its superior sensitivity. With NAAT, the concern is that, because colonization does not necessarily translate to actual infection, the test is too sensitive and results in patients being treated with antibiotics unnecessarily. This increases the risk of antibiotic resistance, and of recurrent CDIs.

There have been attempts to address each technology’s shortcomings by combining them, for example using algorithm-based diagnoses, but these have their own issues and overall, the currently available choices for diagnosing CDI are less than ideal.

Rising to the challenge

Ultra-sensitive immunoassay could bridge the gap by delivering both sensitivity and precision. Diagnostic start-ups such as Quanterix and Singulex are developing an ultra-sensitive immunoassay test. Promising progress has been made, as in October 2018 the Singulex Clarity ultra-sensitive immunoassay test for CDI was registered with the FDA as a Class I device.

Whether this new technology, or any other, will be the answer to the CDI diagnostics controversy remains to be seen. Given the potential impact of a misdiagnosis on the patient's journey, clinicians and laboratory staff may be hesitant to trust a novel technology until they can see completely convincing evidence. Until then, the new technologies will compete against the already-proven options of EIA and NAAT.

Ringing in the new

Introducing a new way to diagnose CDI, changing the minds of healthcare and laboratory professionals, and driving adoption will require a multi-faceted approach, based around education, support, and affordability.

The process must be based on evidence from clinical outcome studies, which can be used to support value propositions and guideline changes. Garnering physician support and creating demand will rely on increasing awareness for the new option, through key opinion leaders, professional groups, conferences, and publications. Success, however, in a time of budget constraints, will depend on the availability of reimbursement.

Related solutions

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Contact Us